Fingolimod HCl CAS 162359-56-0

Product Description:

Product Name: Fingolimod HCl CAS NO: 162359-56-0

Synonyms:

Fingolimod hydrochloride; FTY-720A;

1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-,hydrochloride;

2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride;

2-Amino-2-[2-(4-n-octylphenyl)ethyl]propane-1,3-diol Hydrochloride;

Chemical & Physical Properties:

Appearance : White to off-white solid

Assay : ≥99.0%

Density: 1.016g/cm3

Melting point: 102-107℃

Boiling Point: 479.5℃ at 760 mmHg

Flash Point: 243.8℃

Refractive Index: 1.531

Vapor Pressure: 5.28E-10mmHg at 25°C

PSA: 66.48000

LogP: 4.70660

Solubility: DMSO (Slightly), Methanol (Slightly), Water (Slightly)

Category: Standards; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;

Safety Information:

HS Code: 2922199090

Hazard Declaration: H315; H319; H335; H412

Signal Word: Warning

Caution Statement: P261; P273; P305 + P351 + P338

Symbol: GHS07

Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.

Application:

1.Fingolimod, chemically known as 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride, is an immunosuppressive agent Clinical use for the treatment of recurrent multiple sclerosis.

2. Fingolimod hydrochloride is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells.

Our factory manufacture’s Fingolimod HCl CAS 162359-56-0, mature technology, stable output, quality assurance.

Inventory Status : In Stock.

We can provide CAS 162359-56-0 COA (certificate of analysis), 2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol hydrochloride MOA (Method of Analysis),2-Amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol Hydrochloride ROS (Route of synthesis),2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol chlorhydrate MSDS (Material Safety Data Sheet) and other support for you !

Fingolimod hydrochloride is the first oral drug used to treat multiple sclerosis. It was successfully developed by Novartis Pharmaceuticals and has been approved for marketing by the US Food and Drug Administration (FDA). The recommended dose is 0.5 mg orally once a day. Multiple sclerosis is a debilitating neurological disease that may cause patients to lose balance, muscle cramps and other motor dysfunctions. The disease has always been treated with injectable drugs, which brings great benefits to patients. The inconvenience.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.